Lipocine (LPCN) Receivables (2022 - 2023)
Lipocine's (LPCN) quarterly Receivables came in at $762254.0 in Q4 2023, down 82.72% YoY from $4.4 million in Q4 2022, and up 7.28% on a QoQ basis from $710505.0 in Q3 2023.
Lipocine (LPCN) Receivables (2022 - 2023) Analysis & Trends
Lipocine (LPCN) has 2 years of Receivables data on file, last reported at $762254.0 in Q4 2023.
- Quarterly Receivables fell 82.72% year-over-year to $762254.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $762254.0 (down 82.72% YoY) and the FY2023 annual result came in at $762254.0, down 82.72% from the prior year.
- Receivables improved to $762254.0 in Q4 2023, from $710505.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $4.4 million in Q4 2022 to a low of $710505.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Lipocine | 11.34 Mn | -12.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 762,254.00 |
| Sep 30, 2023 | 710,505.00 |
| Dec 31, 2022 | 4.41 Mn |